Bevacizumab appears effective as an adjunctive treatment in wet AMD patients undergoing cataract surgery

This case series included 20 patients (20 eyes) with predominantly classic CNV due to AMD who underwent phacoemulsification. At the end of surgery all eyes received an intravitreal injection of bevacizumab as an adjunctive tool against surgically induced ocular inflammation. At one month, there was a significant reduction in OCT-measured macular thickness and in corrected distance visual acuity. Researchers observed no intraoperative or postoperative complications.